Business
Half Yearly Report
Half Yearly Report.
About this update from Gunsynd Plc
[{"type":"text","content":"\n RNS Number : 2417R Syntopix Group plc 28 April 2009 \n\n\n\n\n\nEmbargoed for release on 28 April 2009: 7:00am\n\n\n\n\n\n\n\n\nSYNTOPIX GROUP PLC\n('Syntopix' or 'the Company')\n\nInterim results for the six months ended 31 January 2009\n\nSyntopix Group plc (AIM: SYN) the speciality pharmaceutical research and development company focused on dermatological diseases and other conditions requiring antimicrobial compounds today announces its interim results for the six months ended 31 January 2009.\n\n\nHighlights:\n\n\n\nInitiated a further Phase II proof-of-concept clinical study.\n\n\n\n\nOur Exclusivity and Evaluation agreement with a major consumer healthcare company has been renewed for a further 12 months.\n\n\n\n\nAdditional placing in August 2008 raising funding of £1.48 million (net of expenses).\n\n\n\n\nStrong patent portfolio with 17 core patents/applications. 5 patents have been granted in the UK.\n\n\n\n\nDr Stephen Jones (Chief Executive Officer) commented: 'The number of compounds that are entering human use studies for the treatment of several consumer healthcare conditions is steadily increasing, and Syntopix is entering a new, exciting phase.'\n\n\nThese interim results will be made available on the Group's website at www.syntopix.com.\n\n\nEnquiries\n\n\n\n\n\nSyntopix Group plc\n\n\n+ 44 (0) 845 125 9204\n\n\n\n\nDr Rod Adams, Chairman\n\n\n\n\n\n\n\nDr Stephen Jones, Chief Executive Officer\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nZeus Capital Limited\n\n\n+44 (0) 161 831 1512\n\n\n\n\nRoss Andrews\n\n\n\n\n\n\n\nBobby Fletcher\n\n\n\n\n\n\n\n\nNotes to editors\n\nAbout Syntopix Group plc\nSyntopix is a group focused on the discovery and development of drugs for the topical treatment of dermatological diseases and other conditions requiring antimicrobial compounds. The company was founded in 2003 as a spin-out from the University of Leeds by Dr Jon Cove and Dr Anne Eady, two of the leading experts in skin microbiology, with initial funding from The Wellcome Trust.\nSyntopix' strategy is to seek to reduce the risks and costs of drug discovery and development by discovering novel uses for known compounds. The company concentrates on compounds and combinations of compounds that have a hist...